Ireland Defers Decision on Skyclarys for Friedreich's Ataxia Amid Mounting Patient Pressure
核心洞察
The HSE Drugs Group has deferred a decision on reimbursing Skyclarys (omaveloxolone) for Friedreich's ataxia (搜索) for three to four weeks, pending further review.
Taoiseach Micheál Martin acknowledged the "matter of urgency" for families and criticized Biogen for being "slow" in submitting its commercial proposal, received May 27.
Minister for Health Jennifer Carroll MacNeill noted "mixed" evidence across Europe, with only 12 countries approving the drug; Belgium, the Netherlands, and Denmark have not approved it.
The Health Service Executive (HSE) Drugs Group has deferred a decision on whether to fund Skyclarys (omaveloxolone) for Friedreich's ataxia (搜索), pushing the decision back another three to four weeks and intensifying the anguish of families living with the rare degenerative neurological condition.
The deferral, announced Tuesday, means Irish patients continue to wait for access to the first treatment approved for Friedreich's ataxia (搜索)—a drug already greenlit by the U.S. FDA in 2023 and by the European Medicines Agency a year later.
Taoiseach Micheál Martin addressed the delay directly, stating he understood this was a "matter of urgency for those with the condition of Friedreich's Ataxia (搜索)." He also pointed to the manufacturer's role in the timeline. "The commercial proposal was ultimately received from Biogen on May 27. They went through a lot of interactions before that, which could have been quicker, in my view, on the part of the company," Mr. Martin said.
A Family's Devastation
The human toll of the delay is starkly illustrated by the Coady family from Buttevant, County Cork. Paudie Coady, 16, lives with Friedreich's ataxia (搜索), a progressive disease that robs patients of mobility and independence. His 13-year-old brother Rory died from the condition in September 2025. Their mother, Delia, has Huntington's disease (搜索) and is receiving treatment in Dublin.
Craig Coady, the father of both boys, voiced his despair on Cork's Red FM: "We prayed today would finally bring hope for Paudie. Instead we have been told to wait again."
The Coady family is one of approximately 200 families in Ireland affected by Friedreich's ataxia (搜索). Campaigners have repeatedly stressed that every month without access to Skyclarys risks patients losing abilities that cannot be regained, as the drug can slow disease progression but cannot reverse damage already done.
Regulatory Process and European Context
Minister for Health Jennifer Carroll MacNeill defended the review process during a visit to Monaghan Hospital, explaining that every medicine seeking reimbursement must undergo a rigorous two-stage assessment. "With all of the rare disease drugs, with all of the drugs generally, it goes through a two-stage process, testing the effectiveness of it and then seeing how the effectiveness relates to the price," she said.
The Minister acknowledged that the evidence base for Skyclarys is less definitive than for some other medicines. "Across Europe it's a pretty mixed outcome. I think there's only 12 countries that have approved it and a lot of countries our sort of size have not approved it based on that mix of effectiveness and cost," she said, citing Belgium, the Netherlands, and Denmark as countries that have not approved the drug.
The drug costs approximately €280,000 to €300,000 per patient annually. It is publicly funded in a number of European countries, but availability remains patchy.
Addressing reports that some Irish patients may consider relocating abroad to access treatment, Minister Carroll MacNeill cautioned that "there's an idea that it's widely available everywhere else. It isn't necessarily true," noting that several countries comparable in size to Ireland have either declined reimbursement or introduced strict eligibility criteria.
Next Steps
The application has now been referred to the Rare Disease Technical Review Group, composed of clinicians who specialize in treating the condition. The Taoiseach confirmed that "the minister is taking steps to get that established as quickly as possible to assess this."
The HSE Drugs Group is expected to meet within a month to further discuss the drug. No definitive timeline has been given for a final funding decision.
"Our goal is always to try to get effective drugs to our patients. That's what we want to do. That's why we spend nearly €4 billion on drugs every year," Minister Carroll MacNeill said. She also indicated that Ireland is exploring partnerships with other smaller European countries "to increase our opportunity to negotiate" with pharmaceutical companies over high-cost medicines.
For families like the Coadys and campaigners such as Castleshane woman Aoife Gavan—who has said she believes she is "running out of time" to benefit from Skyclarys—the wait continues with no certainty in sight.